The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 192.50
Bid: 185.00
Ask: 200.00
Change: 0.00 (0.00%)
Spread: 15.00 (8.108%)
Open: 192.50
High: 192.50
Low: 192.50
Prev. Close: 197.50
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Beowulf raises funds for Kallak iron ore project

Mon, 04th Mar 2024 19:59

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Beowulf Mining PLC - London-based mining company with projects in Sweden, Finland and Kosovo - Announces terms of previously announced fundraise. Says rights issue of Swedish depository receipts will raise up to GBP6.3 million, while a retail offer of ordinary shares in the UK will raise around GBP1.6 million. Notes the SDRs will be offered at SEK0.08 each and the shares at 0.61 pence each. Adds the SDRs will also be offered for subscription, without preferential rights, to institutional investors, other professional investors and the general public in Sweden. Beowulf says it has has received underwriting commitments for the rights issue for around 60% of the total. Explains proceeds will be used mainly to finance the continued development of the Kallak iron ore project in northern Sweden, including completion of the ongoing pre-feasibility study and environmental studies. Funds will also repay amounts advanced under the bridge loan financing arrangements, and corporate costs.

----------

Kefi Gold & Copper PLC - exploration and development company focused on gold and copper projects in the Arabian-Nubian Shield - Plans to raise GBP4.5 million placing at 0.6 pence per share. Further, issues 83.3 million shares to cover accrued fees to certain directors and advisers. In addition, launches retail offer at the same issue price. Explains funds will underpin the launch of the Tulu Kapi Gold project by mid-2024.

----------

LungLife AI Inc - California-based developer of clinical diagnostic solutions for early lung cancer detection - Plans to raise around GBP1.8 million via a GBP1.56 million placing at 35 pence each and a GBP250,000 subscription at the same price. Explains net proceeds, along with existing cash resources, are expected to be utilised to establish the commercial proof of concept of the company's LungLB test. Notes funding is expected to provide the company with a cash runway to early April 2025.

----------

RC365 Holding PLC - London-based company focusing on payment gateway solutions and IT support services - Enters into an unsecured convertible loan note with Mill End Capital Ltd for up to GBP4 million. Says net proceeds of the unsecured loan will be used for the continuing development of existing operations with a particular focus on expanding operations in Malaysia, Japan and the UK. States the first tranche of the CLN comprises GBP600,000, the second tranche a further GBP1.4 million. Any further tranche shall be at the written request of RC365 and discretion of the lender, but will not exceed GBP4 million, RC365 says.

----------

Faron Pharmaceuticals Ltd - Turku-Finland-based clinical-stage biopharmaceutical company - Announces binding commitments worth GBP3.2 million for convertible loans obtained from certain existing shareholders. Explains this allows it to make critical payments to third parties under agreed waivers with IPF. Says this secures its short-term financing needs until the end of March. Faron says talks continue to secure its short and longer-term financing needs, including first additional bridge financing of around EUR5 million. In addition to the short-term bridge financing, Faron intends to propose to the Annual General Meeting an authorization for a larger share issue. In total, Faron expects to need EUR35 million of financing to complete the enrolment of the phase 2 of the BEXMAB study and to obtain regulatory feedback from the US Food & Drug Administration. At February 19, notes cash and cash equivalents held by Faron totalled EUR4.3 million.

----------

Supernova Digital Assets PLC - looks to identify investment and business building opportunities in the Solana and crypto currency ecosystem - Plans return to shareholders. Intends to achieve this by purchasing its own shares through a tender offer. Further, raises GBP242,000 via placing at 0.1 pence per share.

----------

Celsius Resources Ltd - explorer focused on portfolio of copper-gold resources in the Philippines - Advises that trading will be halted on the Australian Securities Exchange effective from March 5 further to the company's request. Celsius says it requested the suspension ahead of an announcement in relation to its flagship Maalinao-Caigutan-Biyog copper-gold project and the issuance of project sensitive documents by the Philippine National Government. Says trading on the AIM market of the London Stock Exchange remains unaffected.

----------

Kibo Energy PLC - Galway, Ireland-based company with energy projects in Africa and the UK - Sells shares in its subsidiary Mast Energy Developments PLC worth GBP29,350. Notes proceeds will be used to pay down the balance balance on the bridge loan facility with RiverFort Global Opportunities PCC Ltd. Holds 33% stake in MED following the share sale.

----------

Braveheart Investment Group PLC - Dodworth, England-based investment company - Provides update on one of its investments, Paraytec Ltd. Notes Paraytec develops high performance specialist detectors for the analytical and life sciences instrumentation markets. In December, Braveheart sought a buyer for Paraytec, of which it owns 100%. But, notes it has been unable to secure an attractive offer and therefore decides to retain Paraytec within its portfolio.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
31 Oct 2022 19:58

TRADING UPDATES: 4Global wins deal; James Cropper profit warning

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
14 Oct 2022 11:14

Faron Pharmaceuticals shares down as raises EUR8.4 million in placing

(Alliance News) - Faron Pharmaceuticals Ltd shares declined on Friday, after it said it has raised EUR8.4 million from a share placing.

Read more
13 Oct 2022 21:17

TRADING UPDATES: Bidstack names new COO; Fintel expands deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 12:10

REPEAT: Faron Pharma half-year loss widens on higher R&D spending

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widened, as the company reported higher research and administrative expenses and remained revenue-less.

Read more
25 Aug 2022 11:43

Faron Pharmaceuticals half-year loss widens on higher R&D spending

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widen, as the company reported higher research and administrative expenses and remained revenue-less.

Read more
18 Aug 2022 16:02

UK earnings, trading statements calendar - next 7 days

Friday 19 August 
Apax Global Alpha LtdHalf Year Results
Kingspan Group PLCHalf Year Results
Newcrest Mining LtdFull Year Results
Monday 22 August 
Smoove PLCFull Year Results
Tuesday 23 August 
Aferian PLCHalf Year Results
John Wood Group PLCHalf Year Results
Wednesday 24 August 
Costain Group PLCHalf Year Results
Lookers PLCHalf Year Results
Standard Chartered PLCHalf Year Results
Thursday 25 August 
Amigo Holdings PLCQ1 Results
Anglo Pacific Group PLCHalf Year Results
Benchmark Holdings PLCQ3 Results
CRH PLCHalf Year Results
Faron Pharmaceuticals LtdHalf Year Results
Grafton Group PLCHalf Year Results
Harbour Energy PLCHalf Year Results
Hays PLCFull Year Results
Hunting PLCHalf Year Results
Macfarlane Group PLCHalf Year Results
Morses Club PLCFull Year Results
South32 LtdFull Year Results
  
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
30 Jun 2022 15:59

UK shareholder meetings calendar - next 7 days

Friday 1 July 
All Star Minerals PLCGM re name change to Marula Mining
Monday 4 July 
Active Energy Group PLCAGM
Clean Invest Africa PLCAGM
Securities Trust of Scotland PLCAGM
Tuesday 5 July 
Immediate Acquisition PLCAGM
Marks & Spencer Group PLCAGM
Open Orphan PLCAGM
Saga PLCAGM
Smartspace Software PLCAGM
Young & Co's Brewery PLCAGM
Wednesday 6 July 
Assura PLCAGM
ContourGlobal PLCGM re acquisition by KKR
GSK PLCGM re Consumer Healthcare demerger, Haleon listing
Mining Minerals & Metals PLCAGM
PCF Group PLCGM re director allotment authority
Puma Alpha VCT PLCAGM
Shires Income PLCAGM
Sirius Real Estate LtdAGM
Strategic Minerals PLCAGM
Worldwide Healthcare Trust PLCAGM
Thursday 7 July 
C&C Group PLCAGM
Distil PLCAGM
Emmerson PLCAGM
Faron Pharmaceuticals LtdGM re issuance of shares
FD Technologies PLCAGM
Great Portland Estates PLCAGM
Greencare Capital PLCAGM
J Sainsbury PLCAGM
JPMorgan European Growth & Income PLCAGM
Land Securities Group PLCAGM
Likewise Group PLCGM re approval of waiver by takeover/merger panel
N Brown Group PLCAGM
Octopus Apollo VCT PLCAGM
Peel Hunt LtdAGM
Pets At Home Group PLCAGM
Puma VCT 13 PLCAGM
Severn Trent PLCAGM
TomCo Energy PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
28 Jun 2022 18:03

IN BRIEF: Faron raises EUR5 million for bexmarilimab development

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Conducts private placing to raise EUR5 million in 2.0 million newly issued treasury shares at EUR2.49 each. Once the funds are received, Faron expects to have sufficient working capital to last until the first quarter of 2023. Net proceeds will be largely used for the acceleration of the clinical development program and manufacturing of bexmarilimab, its immunotherapy asset.

Read more
15 Jun 2022 19:24

IN BRIEF: Faron Pharma reveals topline results from MATINS trial

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Announces top-line overall survival results from its phase 1/2 'Macrophage Antibody To Inhibit Immune Suppression study, which investigated the safety and efficacy of bexmarilimab monotherapy in ten different hard-to-treat or on operable solid tumour cohorts.

Read more
8 Jun 2022 16:54

IN BRIEF: Faron Pharma doses first patient in bexmarilimab study

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Doses first patient in the phase I/II BEXMAB study. The study is investigating bexmarilimab, Faron's wholly-owned precision immunotherapy asset, in combination with azacitidine in multiple hematological malignancies. This marks the first time bexmarilimab is being assessed as part of a clinical study in hematologic malignancies, Faron explains.

Read more
16 May 2022 17:35

IN BRIEF: US and Finland approve Faron's bexmarilimab study

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - US Food & Drug Administration and Finnish Medicines Agency clear company's investigational new drug application to start its BEXMAB study, which is for assessing the safety, tolerability and efficacy of precision cancer immunotherapy known as bexmarilimab.

Read more
12 May 2022 19:45

TRADING UPDATES: Belluscura to raise GBP5 million; React buys

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Apr 2022 19:30

IN BRIEF: Faron Pharmaceuticals CEO buys shares worth EUR71,000

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Chief Executive Markku Jalkanen buys 25,000 shares at an average price of EUR2.82, worth EUR70,533, on Tuesday.

Read more
5 Apr 2022 20:45

TRADING UPDATES: Rambler ups production; SRT Marine anticipates loss

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
25 Mar 2022 13:21

EARNINGS UPDATES: Everyman revenue doubles; Aeorema in interim profit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.